News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
02 Sep 2024
byAudrey Abella
In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).
02 Sep 2024

Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients
02 Sep 2024
byChristina Lau
Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.
02 Sep 2024






